Jake wrote re LL TNBC conclusive trial:

Quote:

---

In such a trial, meeting an OS primary end point well beyond the reach of Trodelvy would not only virtually guarantee approval, it would throw wide open the door to the huge cold tumor cancer market.

---

If such an outcome is indeed assured, wouldn’t it be more manly for us to self finance this trial even if by a dilution? Like in gambit to sacrifice a figure to win the game. And not to share its spoils with big predators. Just saying...